TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03800732

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: With Meal during night work
Description: Two nights of work with a meal during the shift and after will go to the laboratory the morning for eating a test meal ad libitum, which will consist of foods of various compositions and food groups. Preprandial metabolic assessments will be conducted (ghrelin, GLP-1 - glucagon-like peptide 1, PYY-peptide YY). The following postprandial evaluations will be carried out and in the 24 hours following the experiment: food choices (record of all foods) and food perceptions (hunger, appetite, satiety and eating).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Without Meal during night work
Description: Two nights of work without a meal during the shift and after will go to the laboratory the morning for eating a test meal ad libitum, which will consist of foods of various compositions and food groups. Preprandial metabolic assessments will be conducted (ghrelin, GLP-1 - glucagon-like peptide 1, PYY-peptide YY). The following postprandial evaluations will be carried out and in the 24 hours following the experiment: food choices (record of all foods) and food perceptions (hunger, appetite, satiety and eating).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep night
Description: Two sleep nights and after will go to the laboratory the morning for eating a test meal ad libitum, which will consist of foods of various compositions and food groups. Preprandial metabolic assessments will be conducted (ghrelin, GLP-1 - glucagon-like peptide 1, PYY-peptide YY). The following postprandial evaluations will be carried out and in the 24 hours following the experiment: food choices (record of all foods) and food perceptions (hunger, appetite, satiety and eating).
Study: NCT02166736

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iFR
Description: Treatment guided by Instantaneous wave-free ratio (iFR®)
Study: NCT00045435

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Description: Undergo nonmyeloablative allogeneic PBSC transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Undergo TBI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo nonmyeloablative allogeneic PBSC transplant
Study: NCT03390777

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Description: surgery without the use of prgf

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PRGF after surgery
Description: surgery and application of PRGF
Study: NCT02826967

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonic Irrigation
Study: NCT00738101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omegaven
Description: Therapy with Omegaven will be provided at a dose of 1 gm/kg/day (by continuous infusion). Omegaven will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition. Treatment will be given for as long as the child needs any TPN AND has a conjugated bilirubin greater than 2 mg/dL for a maximum of 5 years. If the infant no longer is requiring any TPN, then the Omegaven will be stopped regardless of bilirubin. If the bilirubin is less than 2 mg/dL but the child still requires TPN, then the Omegaven will be continued until the infant no longer requires TPN.
Study: NCT03573661

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breast Cancer Locator (BCL)
Description: This locator will be constructed pre-operatively, sterilized and provided to the surgeon at the time of procedure. The outline of the breast cancer on the breast surface at the point where the cancer is closest to the skin is built into the locator, so that the surgeon can simply apply the locator to the patient's breast and trace the tumor outline on the skin.
Study: NCT03430141

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritarian Diet-style
Description: Nutritarian Diet-style: Daily consumption of greens, beans/legumes, a variety of other vegetables, fresh or frozen fruits, nuts, seeds and whole grains. Participants are encouraged to minimize consumption of refined grains, vegetable oils, processed foods, and to limit animal products.
Study: NCT01424475

Intervention type: GENETIC
Group type: OTHER
Intervention: Healthy
Description: Healthy Volunteers

Intervention type: GENETIC
Group type: OTHER
Intervention: PKD Patients
Description: PKS Patients
Study: NCT01542060

Intervention type: DRUG
Intervention: biphasic insulin aspart 30
Description: Administered via an insulin injection device. Dosages varied according to individual patients' medical requirement as determined by their attending clinician
Study: NCT01204268

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sev-I group
Description: Sevoflurane will be given before the cerebral artery clip as a preconditioning procedure for the coming ischemia-reperfusion injury.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sevo continuous inhalation
Description: Patients will receive the anesthesia with continuous inhalation of sevoflurane.
Study: NCT02166736

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FFR
Description: Intervention guided by Fractional Flow Reserve
Study: NCT04576364

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulfate for 12 hour
Description: drug used to prevent convulsions in patients having preeclampsia with severe features

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulfate for 24 hour
Description: drug used to prevent convulsions in patients having preeclampsia with severe features
Study: NCT04531566

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Feed
Description: Infant will be seen by occupational therapist (OT) twice a week and assessed for oral cues. If infant shows oral cues then the occupational therapist will proceed with feeding strategies. Oral feeding strategies include pacifier dips, open nipple trials with syringe controlled bolus size (1-4mls) and po trials up to 10mls.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Infants will not start oral feeds until on HFNC 2 Litres or less. Oral feeds will be started on the discretion of the physician.
Study: NCT03909178

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hip Arthroscopy Surgery with Acetabular Labral Repair (SPT group)
Description: Patients randomized to the SPT group provided consent for arthroscopic acetabular labral repair with femoroacetabular osteoplasty. As previously described in various technique publications from our group, the senior surgeon's (S.D.M.) hip arthroscopy technique includes intra-articular fluid distension for initial portal placement, puncture capsulotomy, autograft capsular augmentation if insufficient or degenerative labral tissue is encountered, intermittent traction, sparing use of electrocautery, and preservation of the chrondrolabral junction. All SPT patients underwent a standardized postoperative physical therapy protocol developed jointly by the senior author (a sports medicine fellowship-trained orthopaedic surgeon) and the physical therapists. Patients were kept weightbearing as tolerated on crutches for 6 weeks to maintain a level pelvis without lurching when walking and were instructed to avoid impact loading exercises for 6 months.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy Focused on the Hip and Hemi-pelvis (PT group)
Description: PTA patients were assigned a standardized, 24-week course of supervised, core-based PT. This course was designed in concert with physical therapists within our institution to help address symptoms of labral tear in patients older than 40 who had mild to moderate OA. Weeks 1 and 2 focused on normalizing gait, and weeks 3 through 24 focused on optimizing range of motion (ROM) while slowly integrating strength training. Unlike the prerandomization PT protocol, the PTA protocol was predominantly physical therapist-supervised (at least 1 in-person visit per week).
Study: NCT02355613

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiosurgery with Gamma Knife Perfexion
Description: Gamma Knife Radiosurgery is a very precise form of therapeutic radiology. Even though it is called surgery, a Gamma Knife procedure does not involve actual surgery but it uses 192 isocentric beams of highly-focused gamma rays (60-Co) to treat small to medium size lesions. Minimum beam size is 4 mm. This procedure is frame based.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Linac-based Radiosurgery with EDGE
Description: EDGE linear accelerator from Varian (Varian, Palo Alto, USA) is a C-arm machine specifically developed for radiosurgery frameless treatment. The characteristics of this linac are a high level of precision and the possibility to include multiple positioning systems for stereotactical treatments, among which Cone Beam CT (CBCT), the Optical Surface Monitoring System (OSMS), and Calypso.
Study: NCT01861457

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nozin® Nasal Sanitizer®
Description: The treatment agent tested was the alcohol and natural oil preparation that comprises the commercially available over-the-counter (OTC) product, NOZIN® Nasal Sanitizer® antiseptic, by Global Life Technologies Corp, with the addition of benzalkonium chloride (0.13%), as described for the patented and safety-tested formulation.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo preparation, utilized to account for the potential mechanical effects of the application process, was phosphate buffered saline (PBS).
Study: NCT01786330

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Procare abdominal binder

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Study: NCT03039439

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Previously collected tumor tissue and blood samples

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03201965

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Participants will receive 300 mg/m\^2 of cyclophosphamide as an oral or IV dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Participants will receive 1.3 mg/m\^2 of bortezomib as an subcutaneous (SC) injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone, 40 mg
Description: Participants of CyBorD alone arm will receive 40 mg dexamethasone orally or IV dose. Participants of CyBorD plus daratumumab arm will receive dexamethasone 20 mg orally or IV dose as premedication and 20 mg on the day after daratumumab dosing to make a total of 40 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Participants will receive 1800 mg of daratumumab subcutaneously.
Study: NCT05924399

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Affect Labeling Training
Description: (1) Participants will view combat-relevant images and then label the image or how they feel while viewing the image. (2) Participants will view facial expressions and then label the image. (3) Participants will view negative combat- irrelevant images (such as snakes or spiders) and then label the image or how they feel while viewing the image. (4) Participants will complete Go-NoGo trials similar to the fMRI Go-NoGo task described above. Participants will receive all four types of inhibitory training.
Study: NCT00524030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin 600 mg/day
Description: pregabalin 600 mg/day (300mg BID), duration is 20 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin 150 mg/day
Description: pregabalin 150 mg/day (75mg BID), duration is 20 weeks.
Study: NCT02178644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemo with concomitant Capecitabine and KD018
Description: Patients will receive a course of chemo-radiation with concomitant Capecitabine and KD018, and to compare this to the toxicity seen in patients treated with Capecitabine and radiation therapy alone, in patients with T3-T4 and N0-N2, M0 rectal cancer.
Study: NCT02914132

Intervention type: DEVICE
Group type: OTHER
Intervention: Seraph 100 Filter
Description: Treatment of renal replacement therapy patients with bacteremia.
Study: NCT04254484

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SIESTA Rehab Education
Description: Staff nurses will be trained on how to improve sleep in stroke patients in the acute rehabilitation setting.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ApneaLink
Description: Stroke patients on the SIESTA Rehab unit will be screened for sleep disordered breathing using ApneaLink monitors. Results will be interpreted by a sleep specialist who will then advise the clinical team at SRALab.
Study: NCT01315730

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tactile Stimulation
Description: See Arms
Study: NCT06763978

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcatheter PDA closure
Description: Transcatheter PDA closure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcatheter PDA closure
Description: Transcatheter PDA closure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcatheter PDA closure
Description: Transcatheter PDA closure
Study: NCT03477175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7080
Description: Oral Administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7080
Description: Oral Administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator Drug
Description: Per parent study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator Drug
Description: Per parent study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator Drug: Sorafenib
Description: Per parent study.
Study: NCT02929355

Intervention type: OTHER
Intervention: carotid assesment by duplex ultrasonography
Study: NCT02107794

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Decision Aid
Description: Paper based decision aid will be utilized to facilitate treatment option conversation between clinician and patient.
Study: NCT02335008

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sucralose
Description: 2 packets per 12 fl oz

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sucrose
Description: equisweet to sucralose
Study: NCT00175344

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scar massage.
Description: To objectively evaluate the effects of scar massage, those who agree to participate will be randomly assigned to one of two groups. One group will be taught to perform self-massage of the scars as soon as the scars have adequately healed. The massage should be done about 10 minutes each day for a total of 6 months. The other group will not be taught self-massage and will be asked to not massage their breast scars.
Study: NCT04246372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: Treatment with oral Tofacitinib for immune mediated skin conditions in adults with Down syndrome
Study: NCT01377480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole
Description: POS 40 mg/mL oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole
Description: POS 40 mg/mL oral suspension
Study: NCT01261572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: degarelix
Description: periodic injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: degarelix
Description: periodic injection
Study: NCT02119689

Intervention type: OTHER
Intervention: Diabetic Patients
Description: measuring CD34 cell function in relation to diabetic retinopathy status
Study: NCT01377480

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for posaconazole
Description: Placebo oral suspension
Study: NCT02119689

Intervention type: OTHER
Intervention: Healthy Controls
Description: measuring CD34 cell function
Study: NCT01377480

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for posaconazole
Description: Placebo oral suspension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benznidazole
Description: BNZ 100 mg oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benznidazole
Description: BNZ 100 mg oral tablet
Study: NCT04556994

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Phase 1 Cardiac Rehabilitation
Description: Step 1:Breathing exercises, 3 sets of 10 repetitions. Active upper and lower extremity exercises, 3 sets of 10 repetitions; bed inclined at 45°.~Step 2:Active exercises as in step 1. Stay in the upright position and perform walking on the spot for three series of 1 min.~Step 3:Active exercises as in step 2. Ambulation within the inpatient wards (7 min). Transfer to an allocated chair beside the bed (at least 30 min).~Step 4:Same exercises as in step 3. Ambulation within the inpatient wards (10 min). Transfer to an allocated chair beside the bed (at least 1 h).~Step 5:Same exercises as in step 4. Ambulation within the inpatient wards (15 min). Transfer to an allocated chair beside the bed (at least 2 h).~Step 6:Active exercises from the previous day. Ambulation within the inpatient wards (20 min). Step training (3 times continuously, 20 cm standardized step).~Step 7:Exercises from the previous day. Step training (6 times continuously, 20 cm standardized step).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phase 1 Cardiac Rehabilitation with Lower Limb Paddling
Description: Step 1 to step 6 of Phase 1 Cardiac Rehabilitation given to the patients along with Lower limb exercise on Paddler lasting 20 min (5-min warm-up, 10 min of low-intensity exercise, and 5-min recovery), 30 rpm ( rotation per minute)
Study: NCT05386667

Intervention type: DRUG
Intervention: Majezik %0.25 oral spray
Description: Free gingival graft was taken from the palatal mucosa of the patients in order to increase the attached gingiva.~After FGG, the patients were asked to apply this spray to the palatal mucosa 3 times a day.

Intervention type: OTHER
Intervention: Aftamed oral spray
Description: Free gingival graft was taken from the palatal mucosa of the patients in order to increase the attached gingiva.~After FGG, the patients were asked to apply this spray to the palatal mucosa 3 times a day.

Intervention type: OTHER
Intervention: Crystalin oral spray
Description: Free gingival graft was taken from the palatal mucosa of the patients in order to increase the attached gingiva.~After FGG, the patients were asked to apply this spray to the palatal mucosa 3 times a day.

Intervention type: PROCEDURE
Intervention: Free gingival graft harvesting
Description: Free gingival graft was taken from the palatal mucosa of the patients in order to increase the attached gingiva.

Intervention type: PROCEDURE
Intervention: Free gingival graft harvesting
Description: Free gingival graft was taken from the palatal mucosa of the patients in order to increase the attached gingiva.

Intervention type: PROCEDURE
Intervention: Free gingival graft harvesting
Description: Free gingival graft was taken from the palatal mucosa of the patients in order to increase the attached gingiva.

Intervention type: PROCEDURE
Intervention: Free gingival graft harvesting
Description: Free gingival graft was taken from the palatal mucosa of the patients in order to increase the attached gingiva.
Study: NCT00876915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalteparin injection
Description: Potency is described in international anti-Xa units (IU). One unit (anti-Xa) of dalteparin sodium, average molecular weight 5,000, corresponds to the activity of one unit of the 1st International Standard for Low Molecular Weight Heparin (LMWH)with respect to inhibition of coagulation Factor Xa in plasma utilizing the chromogenic peptide substrate S-2765 (N-alpha-Benzyloxycarbonyl-D-arginyl-glycyl-arginine-pNA.2HCl).
Study: NCT03333915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamiparib
Description: Pamiparib is provided as oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamiparib
Description: Pamiparib is provided as oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamiparib
Description: Pamiparib is provided as oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamiparib
Description: Pamiparib is provided as oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamiparib
Description: Pamiparib is provided as oral capsules
Study: NCT01544166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol (Gadavist, BAY86-4875)
Description: Single intravenous bolus injection of gadobutrol 0.1 mmol/kg BW in term newborns to infants \<2 years of age.
Study: NCT02079948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate + Folic Acid
Description: Participants in the methotrexate + folic acid condition will have a~* Blood draw at each monthly visit~* Cognitive performance testing to assess memory performance~* Physical function testing to assess walking speed and measure muscle endurance~* Pain assessment testing to assess the presence and location of daily pain~* Self-reported function and quality of life to measure disability and mobility limitations, and~* Depression assessment testing to assess participants' level of depression.
Study: NCT00695786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study: NCT02699502

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: matching an appropriate drug therapy to patients with osteoporotic hip fractures
Description: The process involves reviewing patients characteristics virtually and finding the right drug for them while they are still in the hospital. After matching an appropriate drug, getting it through regulatory authorities to the family physician
Study: NCT02162771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Study: NCT02629835

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: intravenous 8 mg dexamethasone and perineural 0.8 ml of saline solution

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: intravenous 0,8 ml of saline solution and perineural 8 mg of dexamethasone